Skip to content
Themis Medicare logo

Themis Medicare

THEMISMED NSE
₹98.44 2.71 (2.83%)
Market Cap
₹907 Cr
P/E
22.63

Themis Medicare (THEMISMED) share price was ₹98.44 at the 28 Oct 2026 close; market capitalisation ₹907 Cr; P/E (TTM) 22.63; sector Healthcare. The share price fell 23.0% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue fell 10.9% year on year to ₹87.0 Cr and net profit was ₹25 Cr, against −₹14 Cr a year earlier (compared with Jun 2025). Promoters held 67.11% of Themis Medicare in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 41/100 (Weak) as of 28 Oct 2026.

Close 28 Oct 2026 ₹98.44 −29.37 −22.98% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹907 Cr
P/E (TTM)
22.63
EBITDA
₹9.80 Cr
Return on Equity
0.29%
Debt to Equity
0.25
Book Value
₹39.74
EPS (TTM)
₹4.35
52W High
₹140.60
52W Low
₹64.95

Price-based figures as of 28 Oct 2026, 15:51 IST · EPS basis: Consolidated · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,757.5034.864,21,683 Cr5.050.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,558.5086.752,53,748 Cr15.140.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,557.0071.541,73,334 Cr9.430.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,181.90107.801,17,891 Cr22.240.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,175.5026.161,17,257 Cr4.330.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,335.4034.591,11,463 Cr2.870.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,365.6032.721,10,321 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Themis Medicare (this company)
₹98.4422.63907 Cr2.480.52%0.29%2.92%451 Cr40 Cr
Median 8 companies₹1,561.5534.731,17,574 Cr4.690.57%12.98%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100. How it works →

As of 2026-10-28
v2.0.0
41 Weak
Overall score
Data confidence 100/100
pledge:46%

Category scores

Quality Poor 33
Returns, margins, earnings quality 22%
Valuation Strong 69
Cheap vs sector & own history 24%
Growth Poor 3
Sales & profit trajectory 9%
Financial Health Average 45
Solvency, leverage, coverage 9%
Momentum Poor 34
Trend strength, vol-adjusted 12%
Ownership Average 49
FII/DII/promoter flows 24%

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company has been maintaining a healthy dividend payout of 143%

Weaknesses

5
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 8.21% over past five years.
  • Company has a low return on equity of 6.41% over last 3 years.
  • Promoters have pledged 45.8% of their holding.
  • Company has high debtors of 190 days.

Technical Indicators

Oscillators

BearishNeutralBullish

Bearish

Bearish
3
Neutral
5
Bullish
1

Overall

BearishNeutralBullish

Bearish

Bearish
13
Neutral
5
Bullish
1

Moving Averages

BearishNeutralBullish

Bearish

Bearish
10
Neutral
0
Bullish
0

Growth Rate

Revenue Growth
-14.29% lower than 3Y

change over 1 year

Net Income Growth
-96.31% lower than 3Y

change over 1 year

Cash Flow Change
-109%

change over 1 year

EBITDA Margin Change
-78.85%

change over 1 year Operating margin -60% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
97
105
83
98
123
117
94
72
98
78
90
77
87
Expenses
75
92
74
89
94
100
88
79
108
81
80
73
139
Operating Profit
22
12
8
9
29
17
6
-8
-10
-3
10
4
-52
OPM %
22%
12%
10%
10%
24%
15%
6%
-11%
-10%
-4%
11%
4.9%
-60%
Other Income
6
7
6
5
7
6
1
2
1
5
6
11
97
Interest
2
2
3
2
2
2
3
2
2
3
3
3
3
Depreciation
3
3
3
3
2
2
3
3
3
3
3
3
3
PBT
23
14
8
9
31
18
2
-11
-14
-3
10
9
39
Tax %
19%
19%
10%
24%
21%
20%
69%
-13%
1%
5%
3%
2%
36%
Net Profit
18
11
7
7
25
14
1
-10
-14
-4
10
9
25
EPS (₹)
1.98
1.23
0.8
0.72
2.68
1.55
0.06
-1.05
-1.54
-0.39
1.1
0.97
2.67
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
202
232
217
210
184
202
231
395
354
382
406
342
332
Expenses
184
194
184
184
181
166
181
299
287
330
356
342
374
Operating Profit
18
38
33
25
2
36
49
96
67
52
49
0
-42
OPM %
9%
16%
15%
12%
1.2%
18%
21%
24%
19%
13%
12%
0.1%
-13%
Other Income
13
3
4
6
5
12
13
18
25
24
11
23
118
Interest
15
12
12
12
12
13
13
9
10
9
10
11
11
Depreciation
11
12
7
7
8
8
9
9
10
12
10
10
10
PBT
5
17
18
11
-13
27
41
95
73
53
40
2
55
Tax %
-20%
11%
9%
1%
-15%
8%
14%
23%
22%
19%
25%
40%
—
Net Profit
6
16
16
11
-11
25
36
73
57
44
30
1
40
EPS (₹)
0.73
1.91
1.77
1.23
-1.17
2.7
3.88
7.92
6.18
4.73
3.24
0.12
4.35
Div. Payout %
25%
9%
0%
0%
0%
6%
11%
6%
8%
11%
15%
404%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
8
9
9
9
9
9
9
9
9
9
9
9
Reserves
51
66
143
160
149
174
209
278
330
368
393
389
Borrowings
140
128
82
80
82
100
87
80
92
96
83
100
Other Liabilities
77
73
54
56
74
67
65
61
82
93
102
99
Total Liabilities
277
275
289
305
314
350
371
428
514
566
588
598
Fixed Assets
122
117
124
126
123
116
133
144
162
168
172
167
CWIP
4
6
9
2
2
8
2
3
3
3
3
2
Investments
5
6
23
24
27
35
45
56
70
89
95
109
Other Assets
146
146
133
153
162
191
191
225
279
307
318
320
Total Assets
277
275
289
305
314
350
371
428
514
566
588
598
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
19
26
-2
8
11
0
57
34
16
22
35
-3
Investing
-6
-7
-4
0
-4
-5
-16
-16
-24
-16
-12
-3
Financing
-18
-13
5
-9
-10
7
-26
-18
0
-9
-26
4
Net Cash Flow
-5
5
0
-1
-3
2
16
1
-8
-3
-3
-2
Free Cash Flow
13
18
-7
5
5
-5
39
15
-13
4
21
-8
CFO/EBITDA
101
73
-5
29
490
2
115
55
48
60
93
782
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
82
75
81
120
145
186
123
93
149
170
159
190
Inventory Days
246
243
250
253
287
315
272
150
213
188
233
229
Days Payable
237
145
163
156
187
171
143
79
123
126
142
143
Cash Conversion Cycle
91
172
168
216
244
330
251
164
239
232
250
275
Working Capital Days
-20
-17
-16
19
-1
37
51
72
110
114
121
138
ROCE %
9%
15%
13%
10%
-1%
15%
18%
30%
20%
14%
10%
3%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Themis Medicare insights

76 extracted metrics + investor summaries across FY11–FY27.

Shareholding Pattern

DIIs0.01%Promot.67.11%FIIs0.01%Others9.62%Public23.26%As ofSep 2026
45.82% of promoter holding pledged as of Sep 2026

Documents

1
Concall - Aug 2026 Aug 2026
2
Concall - Aug 2026 Aug 2026
3
Concall - May 2026 May 2026
4
Concall - Feb 2026 Feb 2026
5
Concall - Nov 2025 Nov 2025

Frequently Asked Questions about Themis Medicare

What does Themis Medicare Ltd do?
Incorporated in 1969, Themis Medicare manufactures Formulation and API pharmaceutical products[1]
Where is Themis Medicare Ltd (THEMISMED) listed?
Themis Medicare Ltd trades as THEMISMED on the NSE and under code 530199 on the BSE.
Which sector does Themis Medicare Ltd belong to?
Themis Medicare Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Themis Medicare Ltd?
Themis Medicare Ltd has a market capitalisation of ₹906.63 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Themis Medicare Ltd?
Themis Medicare Ltd trades at a PE ratio of 22.63 as of 28 Oct 2026, on earnings per share of ₹4.35, against a book value of ₹39.74 per share.
What is the 52-week high and low of Themis Medicare Ltd?
Over the last 52 weeks Themis Medicare Ltd has traded between ₹64.95 and ₹140.6 as of 28 Oct 2026.
Does Themis Medicare Ltd pay dividends?
Themis Medicare Ltd has a dividend yield of 0.52%.
What is the Return on Equity (ROE) of Themis Medicare Ltd?
Themis Medicare Ltd reported a return on equity of 0.29%. Its debt-to-equity ratio is 0.25.

Company Information

Incorporated in 1969, Themis Medicare manufactures Formulation and API pharmaceutical products[1]

Website themismedicare.com
CEO Dr. Dinesh Shantilal Patel CChem., FRSC(Lond.), Ph.D.
Employees 1,702
Listed 2007-04-02
Face Value ₹ 1
Shares Outstanding 9,21,00,120

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/THEMISMED.md for Themis Medicare Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month